These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Anti-Angiogenic Tyrosine Kinase Inhibitors and Reversible Posterior Leukoencephalopathy Syndrome: Could Hypomagnesaemia Be the Trigger? Shah RR Drug Saf; 2017 May; 40(5):373-386. PubMed ID: 28181126 [TBL] [Abstract][Full Text] [Related]
4. Sorafenib-induced reversible posterior leukoencephalopathy in patients with renal cell carcinoma: A report of two cases. Furubayashi N; Negishi T; Iwai H; Nagase K; Nakamura M Mol Clin Oncol; 2017 Aug; 7(2):281-284. PubMed ID: 28781802 [TBL] [Abstract][Full Text] [Related]
5. Reversible posterior leukoencephalopathy syndrome during regorafenib treatment: a case report and literature review of reversible posterior leukoencephalopathy syndrome associated with multikinase inhibitors. Myint ZW; Sen JM; Watts NL; Druzgal TJ; Nathan BR; Ward MD; Boyer JE; Fracasso PM Clin Colorectal Cancer; 2014 Jun; 13(2):127-30. PubMed ID: 24461491 [No Abstract] [Full Text] [Related]
6. Reversible posterior leucoencephalopathy syndrome in an elderly male on sunitinib therapy. Padhy BM; Shanmugam SP; Gupta YK; Goyal A Br J Clin Pharmacol; 2011 May; 71(5):777-9. PubMed ID: 21480952 [TBL] [Abstract][Full Text] [Related]
14. [Reversible posterior leukoencephalopathy syndrome in a patient presenting granulomatosis with polyangiitis]. Chaput L; Rabot N; Limousin N; Cottier JP; Lioger B; Samimi M Ann Dermatol Venereol; 2017 Feb; 144(2):113-120. PubMed ID: 27502754 [TBL] [Abstract][Full Text] [Related]
15. A man in his 50s with neurological symptoms during cancer treatment. Aanes SG; Nieder C; Prytz J; Odeh F Tidsskr Nor Laegeforen; 2018 Oct; 138(17):. PubMed ID: 30378405 [TBL] [Abstract][Full Text] [Related]
16. [Reversible posterior leukoencephalopathy syndrome (RPLS) associated with Wegener's granulomatosis: a case report and review of the literature]. Onozawa R; Tsuboi Y; Obata T; Inoue H; Yamada T; Miyake K Rinsho Shinkeigaku; 2012; 52(8):567-70. PubMed ID: 22975855 [TBL] [Abstract][Full Text] [Related]
17. Posterior reversible encephalopathy syndrome (PRES) induced by pazopanib, a multi-targeting tyrosine kinase inhibitor, in a patient with soft-tissue sarcoma: case report and review of the literature. Deguchi S; Mitsuya K; Nakasu Y; Hayashi N; Katagiri H; Murata H; Wasa J; Takahashi M; Endo M Invest New Drugs; 2018 Apr; 36(2):346-349. PubMed ID: 29067537 [TBL] [Abstract][Full Text] [Related]
18. Posterior reversible encephalopathy syndrome possibly induced by pemetrexed maintenance therapy for lung cancer: a case report and literature review. Smets GJ; Loyson T; Van Paesschen W; Demaerel P; Nackaerts K Acta Clin Belg; 2018 Oct; 73(5):382-388. PubMed ID: 29173113 [TBL] [Abstract][Full Text] [Related]
19. Pazopanib induced unilateral posterior reversible encephalopathy syndrome. Arslan BM; Bajrami A; Demir E; Cabalar M; Yayla V Ideggyogy Sz; 2017 Mar; 70(3-4):140-144. PubMed ID: 29870619 [TBL] [Abstract][Full Text] [Related]
20. Spectrum and potential pathogenesis of reversible posterior leukoencephalopathy syndrome. Li Y; Gor D; Walicki D; Jenny D; Jones D; Barbour P; Castaldo J J Stroke Cerebrovasc Dis; 2012 Nov; 21(8):873-82. PubMed ID: 21703874 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]